ESMO Breast 2020: will you be among the contributors to the latest data in breast cancer? Submit your abstract by 4 February 2020
The latest standards in the field. Register now to discover them
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Giuseppe Curigliano, ESMO Breast Cancer Co-Chair, shares his thoughts about the upcoming edition of the Congress and the reasons why oncologists should ensure they present their new data at this meeting.
11 Dec 2019
The results from the ALCYONE study
10 Dec 2019
Abstracts are available on OncologyPRO
10 Dec 2019
ESMO would like to thank ECPC for providing translation into Finnish
09 Dec 2019
Evidence for efficacy is based on the results from the IMpower130 study
06 Dec 2019
It is a major public health problem particularly in less-resourced countries
05 Dec 2019
Evidence for efficacy for crizanlizumab-tmcais based on the results from theSUSTAIN trial and for voxelotor on the results from the HOPE study
Geneva, Switzerland
11 Dec
- 14 Dec
2019
Milan, Italy
03 Feb
- 05 Feb
2020
Cape Town, South Africa
13 Feb
- 14 Feb
2020
Cape Town, South Africa
14 Feb
- 16 Feb
2020
Mumbai, India
28 Feb
- 01 Mar
2020
Paris, France
02 Mar
- 04 Mar
2020
